Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis (P7-6.009)
The primary aim of this study is to confirm the age-appropriate dose of efgartigimod coformulated with recombinant hyaluronidase (efgartigimod PH20 SC).
Authors
- Tonke Van Bragt
- Abigail Schwaede (ORCID: https://orcid.org/0000-0002-2574-2217)
- Nancy L. Kuntz (ORCID: https://orcid.org/0000-0003-2253-5156)
- Sithara Ramdas (ORCID: https://orcid.org/0000-0003-3790-2190)
- Anna Kostera‐Pruszczyk (ORCID: https://orcid.org/0000-0002-7309-1914)
- Anna Bogatyreva
- Flavia Menezes
- Juliette Giacobbe
Institutions
- Lurie Children's Hospital (US)
- Medical University of Warsaw (PL)
- John Radcliffe Hospital (GB)
- Argenx (Belgium) (BE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210431
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00